The FDA has granted approval to adjuvant cemiplimab treatment for patients with high-risk cutaneous squamous cell carcinoma ...

Following imlunestrant’s approval, Komal Jhaveri, MD, FACP, compares the oral SERD to its counterpart, elacestrant, in terms of composition and trials.

A network to connect patients with unused medications with patients in need brought $18 million of free cancer medication ...

Panelists discuss how the subcutaneous nivolumab data demonstrate reassuring safety with minimal grade 3/4 events, how ...

AI-driven decision support can ease oncologists’ workloads and streamline care without reducing autonomy.

Learn the critical factors in determining prophylaxis for venous thromboembolism, a frequent and serious complication for ...